Turtle Creek Wealth Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-475
Closed -$25.7K 558
2026
Q1
$25.7K Buy
+475
New +$26.5K ﹤0.01% 448

Other funds holding XPH

Turtle Creek Wealth Advisors's XPH Position: Q2 2026 in Review

Turtle Creek Wealth Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2026, closing a stake of 475 shares — an estimated $25.7K sold.

Turtle Creek Wealth Advisors first reported a position in XPH in Q1 2026 and held it in 1 quarter. The position peaked at $25.7K in Q1 2026. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

  • Turtle Creek Wealth Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
  • Turtle Creek Wealth Advisors sold 475 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $25.7K.
  • Turtle Creek Wealth Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2026 and held it in 1 quarter.
  • Turtle Creek Wealth Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $25.7K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Turtle Creek Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.